Enfermedad renal crónica y dislipidemia
- Pascual, Vicente
- Serrano, Adalberto
- Pedro-Botet, Juan
- Ascaso, Juan
- Barrios, Vivencio
- Millán, Jesús
- Pintó, Xavier
- Cases, Aleix
ISSN: 0214-9168, 1578-1879
Año de publicación: 2017
Volumen: 29
Número: 1
Páginas: 22-35
Tipo: Artículo
Otras publicaciones en: Clínica e investigación en arteriosclerosis
Objetivos de desarrollo sostenible
Resumen
Chronic kidney disease (CKD) has to be considered as a high, or even very high risk cardiovascular risk condition, since it leads to an increase in cardiovascular mortality that continues to increase as the disease progresses. An early diagnosis of CKD is required, together with an adequate identification of the risk factors, in order to slow down its progression to more severe states, prevent complications, and to delay, whenever possible, the need for renal replacement therapy. Dyslipidaemia is a factor of the progression of CKD that increases the risk in developing atherosclerosis and its complications. Its proper control contributes to reducing the elevated cardiovascular morbidity and mortality presented by these patients. In this review, an assessment is made of the lipid-lowering therapeutic measures required to achieve to recommended objectives, by adjusting the treatment to the progression of the disease and to the characteristics of the patient. In CKD, it seems that an early and intensive intervention of the dyslipidaemia is a priority before there is a significant decrease in kidney function. Treatment with statins has been shown to be safe and effective in decreasing LDL-Cholesterol, and in the reduction of cardiovascular events in individuals with CKD, or after renal transplant, although there is less evidence in the case of dialysed patients.